Arcturus Therapeutics Holdings Inc. current report, 30 June 2023

Full document

Arcturus Therapeutics Holdings Inc. — Form 8-K Summary

Business Context and Reporting Period

Arcturus filed a Form 8-K dated June 30, 2023, under Item 7.01 to furnish information regarding regulatory and commercial activities for ARCT-154, its self-amplifying mRNA COVID-19 vaccine candidate. This is an event-based filing and does not provide quarterly or annual financial results for the period ended June 30, 2023.

Key Financial and Operating Metrics

  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
  • No financial statements are included. Exhibit 99.1 is a press release from Meiji Holdings Co., Ltd.

Material Changes and Developments

  • Meiji Seika Pharma Co., Ltd., a subsidiary of Meiji Holdings, submitted an additional application in Japan for a booster dose of ARCT-154 for primary immunization against COVID-19 in adults.
  • The submission follows Meiji’s April 28, 2023 announcement regarding a New Drug Application for two-dose primary immunization with ARCT-154 in adults in Japan.
  • Under a previously announced distribution agreement, Meiji partnered with CSL Seqirus to distribute and sell ARCT-154 in Japan.
  • Arcturus’s global collaboration and license agreement with CSL Seqirus became effective on December 8, 2022. The agreement covers exclusive global rights to research, develop, manufacture, and commercialize Arcturus’s self-amplifying mRNA vaccines for COVID-19, influenza, and three other respiratory infectious diseases, with nonexclusive rights for pandemic pathogens.

Guidance, Outlook, Risks, and Unusual Items

  • The filing provides no financial guidance or quantitative outlook.
  • Regulatory applications and future commercialization depend on regulatory review, clinical outcomes, manufacturing, distribution, and market acceptance.
  • The filing states that forward-looking statements regarding the CSL Seqirus and Meiji collaborations and clinical trial outcomes involve substantial risks and uncertainties.
  • Investors are referred to the risk factors in Arcturus’s most recent Form 10-K and subsequent SEC filings. The company disclaims an obligation to update forward-looking statements.
  • The Item 7.01 disclosure and Exhibit 99.1 are furnished, not filed for purposes of Section 18 of the Exchange Act, and are not incorporated by reference into other filings unless expressly specified.

Important Facts for Investors to Verify

  1. Regulatory status and timing of Japan’s ARCT-154 applications, including the booster-dose application.
  2. Terms, economics, geographic scope, and performance obligations under the CSL Seqirus collaboration and Meiji distribution arrangements.
  3. Clinical efficacy, safety, and regulatory outcomes for ARCT-154.
  4. Financial impact, if any, of the collaboration, licensing, distribution, manufacturing, or commercialization arrangements, which is not quantified in this filing.
  5. Current liquidity, funding requirements, and risk factors in Arcturus’s latest periodic SEC filing.